About prime medicine inc - PRME
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
PRME At a Glance
Prime Medicine, Inc.
60 First Street
Cambridge, Massachusetts 02141-2300
| Phone | 1-617-465-0013 | Revenue | 2.98M | |
| Industry | Biotechnology | Net Income | -195,882,000.00 | |
| Sector | Health Technology | Employees | 214 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PRME Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 116.096 |
| Price to Book Ratio | 2.501 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.002 |
| Enterprise Value to Sales | 65.929 |
| Total Debt to Enterprise Value | 0.207 |
PRME Efficiency
| Revenue/Employee | 13,939.252 |
| Income Per Employee | -915,336.449 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.007 |
PRME Liquidity
| Current Ratio | 5.582 |
| Quick Ratio | 5.582 |
| Cash Ratio | 5.017 |
PRME Profitability
| Gross Margin | -105.431 |
| Operating Margin | -6,787.362 |
| Pretax Margin | -6,566.611 |
| Net Margin | -6,566.611 |
| Return on Assets | -48.544 |
| Return on Equity | -136.875 |
| Return on Total Capital | -101.00 |
| Return on Invested Capital | -119.529 |
PRME Capital Structure
| Total Debt to Total Equity | 26.637 |
| Total Debt to Total Capital | 21.034 |
| Total Debt to Total Assets | 8.323 |
| Long-Term Debt to Equity | 24.277 |
| Long-Term Debt to Total Capital | 19.171 |